
Sugar-Funded Study Questions Evidence Supporting Sugar Intake Guidelines
A study that purported to doubt on the scientific evidence supporting current sugar intake guidelines has been criticized for its funding source: the sugar, food, and beverage industries.
A study attempting to cast doubt on the scientific evidence supporting current sugar intake guidelines has been criticized for its funding source: the sugar, food, and beverage industries.
The
After grading each guideline on 6 domains using the Appraisal of Guidelines for Research and Evaluation, 2nd edition, the study found that only the guidelines issued by the Australian National Health and Medical Research Council met the “acceptable” threshold of a score of 60% or more for all 6 domains.
The lowest median score of the guidelines at 33.3% was for the domain of editorial independence, which relates to “unbiased formulation of recommendations and competing interests.” This domain could also be considered the most ironic, as the authors were themselves funded by competing interests.
In the study’s methods section, the authors acknowledged that the research was supported by the North American branch of the International Life Sciences Institute (ILSI), but wrote that “the funding source had no role in the conduct of the review or the interpretation of data, manuscript review, or publication decision.”
Critics claim that a study receiving support from ILSI, which is funded by global food companies including Coca-Cola, Hershey’s, and Kellogg’s, cannot be relied upon to draw impartial conclusions. The
An
The practice of these companies funding sympathetic research is not a new phenomenon. An
According to the New York Times article, some experts say this most recent study “appeared to be an attempt by the industry to undermine sugar guidelines,” drawing comparisons to the tactics employed by tobacco companies in earlier decades. Beginning in the Great Depression, the cigarette industry paid off scientists to cast doubt on the risk of cancer associated with smoking.
In May, FDA finalized a new
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.















































